摘要
肺动脉高压(PAH)是一种进行性发展的疾病,尽管近年来药物治疗取得了一些进展,但是仍然不能治愈PAH。PAH患者血浆apelin水平较正常人减低,且在肺血管内皮细胞上的表达减少。不仅如此,apelin在调节血管内皮细胞和平滑肌细胞增生与凋亡以及血管重构方面起着一定的作用;在循环系统,apelin可以增加一氧化氮合酶的表达、抑制血管紧张素Ⅱ收缩血管、增加心肌收缩力和心肌保护。Apelin及其孤儿G蛋白偶联受体存在于肺组织,且受缺氧、骨形态蛋白2型受体和血管紧张素Ⅱ调节。因此,apelin有望成为PAH的新型标志物,为PAH提供新的治疗手段。
Pulmonary arterial hypertension （PAH）is a progressive disease. Despite progress in pharmaco- logical therapy,there is still no cure for PAH. Patients with PAH have lower levels of plasma-apelin, and decreased apelin expression in pulmonary endothelial cells. Furthermore, apelin plays a role in angiogenesis and regulates endothelial and smooth muscle cell apoptosis and proliferation. In the systemic circulation, ape- lin modulates endothelial nitric oxide synthase （eNOS）expression, counteracts angiotensin-II mediated vaso- constriction, and has positive inotropic and cardioprotective effects. The peptide apelin and the G-protein cou- pled apelin receptor are expressed in lung tissue, which are regulated by hypoxia, bone morphogenetie protein type 2 receptor and angiotensin 11. Thus, apelin can be used as a new interesting marker for PAH treatment.
出处
《医学综述》
2014年第1期1-3,共3页
Medical Recapitulate
基金
国家自然科学基金(81170094)
